Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenabasum in dermatomyositis
NCT03813160Phase 3Completed
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Dec 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of lenabasum in dermatomyositis (DM) (3 arms), sponsored by Corbus Pharmaceuticals Holdings, Inc. Primary endpoint: Total Improvement Score at 28 weeks. Started Dec 2018; status: completed.
02
Drugs
lenabasum
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT03813160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813160.